# US 2021/0171441 A1 · Phenyl derivatives as cannabinoid receptor 2 agonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171441 A1
- Document ID: US20210171441A1
- Status: Published application
- Kind: A1
- Application number: 16/930,013
- Filed: 2020-07-15
- Published: 2021-06-10
- Earliest claimed: 2015-12-09
- Assignees: Hoffmann-La Roche Inc.
- Applicants: Hoffmann-La Roche Inc.
- Inventors: Olivier Gavelle; Uwe Grether; Matthias Nettekoven; Stephan Roever; Mark Rogers-Evans; Didier Rombach
- Web page: https://patentgrep.com/patent/US20210171441A1

## CPC

- C07C 235/52: having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/12: of the kidneys
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/00: Drugs for skeletal disorders
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 231/02: from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
- C07C 235/48: having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C 237/22: having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated (peptides C07K)
- C07D 205/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 207/10: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 207/14: Nitrogen atoms not forming part of a nitro radical
- C07D 207/16: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 209/54: Spiro-condensed
- C07D 213/61: Halogen atoms or nitro radicals
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 271/06: 1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D 277/28: Radicals substituted by nitrogen atoms
- C07D 277/30: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 305/06: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
- C07D 305/08: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
- C07D 331/04: Four-membered rings
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 403/10: linked by a carbon chain containing aromatic rings
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 413/10: linked by a carbon chain containing aromatic rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07B 2200/07: Optical isomers
- C07C 2601/02: with a three-membered ring
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The invention relates to a compound of formula (I) wherein R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

## Claims

### Claim 1

A compound of formula (I)
wherein
R1 is cyclopropyl, alkyl or haloazetidinyl;
R2 is cyclopropylmethoxy, alkoxy, haloalkoxy, halopyridinyl, alkylpyrazolyl or halopyrrolidinyl;
provided that at least one of R1 and R2 is cyclopropyl or cyclopropylmethoxy;
R3 is —C(O)—NH—C(R4R5)—R6, —C(O)—R7 or R8;
R4 and R5 are independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, alkylsulfonylalkyl and alkyloxetanyl;
or R4 and R5 together with the carbon atom to which they are attached form oxetanyl or dioxothiethanyl;
R6 is aminocarbonyl, 5-methyl-1,2,4-oxadiazol-3-yl, hydroxyalkyl, thiazolyl, alkoxycarbonyl, carboxy, difluoroazetidinylcarbonyl, 5-amino-1,2,4-oxadiazol-3-yl, alkylaminocarbonyl or aminocarbonylalkyl;
R7 is (aminocarbonyl)(difluoro)pyrrolidinyl or (aminocarbonyl)azaspiro[2.4]heptyl; and
R8 is 3-alkyl-1,2,4-oxadiazol-5-yl or 5-alkyl-1,2,4-oxadiazol-3-yl;
or a pharmaceutically acceptable salt or ester thereof.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein R1 is cyclopropyl.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein R2 is cyclopropylmethoxy, alkoxy, haloalkoxy or halopyrrolidinyl.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein R2 is cyclopropylmethoxy, propyloxy, fluoroethoxy, trifluoroethoxy or difluoropyrrolidinyl.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein R4 and R5 are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl and cycloalkylalkyl.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein R4 and R5 are independently selected from the group consisting of hydrogen, methyl, butyl, cyclopropyl and cyclopropylmethyl.

### Claim 7 (depends on 1)

The compound according to claim 1, wherein R6 is aminocarbonyl, 5-methyl-1,2,4-oxadiazol-3-yl, hydroxyalkyl or alkylaminocarbonyl.

### Claim 8 (depends on 1)

The compound according to claim 1, wherein R6 is aminocarbonyl, 5-methyl-1,2,4-oxadiazol-3-yl, hydroxymethyl or methylaminocarbonyl.

### Claim 9 (depends on 1)

The compound according to claim 1, wherein R7 is (aminocarbonyl)(difluoro)pyrrolidinyl.

### Claim 10 (depends on 1)

The compound according to claim 1, wherein R8 is 3-tert-butyl-1,2,4-oxadiazol-5-yl, 5-tert-butyl-1,2,4-oxadiazol-3-yl or 5-methyl-1,2,4-oxadiazol-3-yl.

### Claim 11 (depends on 1)

The compound according to claim 1, wherein the compound is selected from the group consisting of:
(R)-N-(1-amino-4-methyl-1-oxopentan-2-yl)-3-(cyclopropylmethoxy)-4-methylbenzamide;
3-(cyclopropylmethoxy)-4-methyl-N-[2-(5-methyl-1,2,4-oxadiazol-3-yl)propan-2-yl]benzamide;
4-cyclopropyl-3-(cyclopropylmethoxy)-N-[2-(5-methyl-1,2,4-oxadiazol-3-yl)propan-2-yl]benzamide;
N2-[4-cyclopropyl-3-(cyclopropylmethoxy)benzoyl]-L-leucinamide;
4-cyclopropyl-3-(cyclopropylmethoxy)-N-(1-hydroxy-2-methylpropan-2-yl)benzamide;
4-cyclopropyl-3-(cyclopropylmethoxy)-N-[2-(1,3-thiazol-2-yl)propan-2-yl]benzamide;
ethyl 2-[4-cyclopropyl-3-(cyclopropylmethoxy)benzamido]-2-ethylbutanoate;
2-[4-cyclopropyl-3-(cyclopropylmethoxy)benzamido]-2-ethylbutanoic acid;
4-cyclopropyl-3-(cyclopropylmethoxy)-N-[3-(3,3-difluoroazetidine-1-carbonyl)pentan-3-yl]benzamide;
3-(cyclopropylmethoxy)-4-(3,3-difluoroazetidin-1-yl)-N-[2-(5-methyl-1,2,4-oxadiazol-3-yl)propan-2-yl]benzamide;
N-[2-(5-amino-1,2,4-oxadiazol-3-yl)propan-2-yl]-3-(cyclopropylmethoxy)-4-(3,3-difluoroazetidin-1-yl)benzamide;
N2-[3-(cyclopropylmethoxy)-4-(3,3-difluoroazetidin-1-yl)benzoyl]-N-methyl-L-leucinamide;
3-(cyclopropylmethoxy)-4-(3,3-difluoroazetidin-1-yl)-N-[(2S)-1-hydroxy-4-methylpentan-2-yl]benzamide;
3-tert-butyl-5-[4-cyclopropyl-3-(cyclopropylmethoxy)phenyl]-1,2,4-oxadiazole;
N-[3-(2-amino-2-oxoethyl)oxetan-3-yl]-4-cyclopropyl-3-(cyclopropylmethoxy)benzamide;
N-[3-(2-amino-2-oxoethyl)-1,1-dioxothietan-3-yl]-4-cyclopropyl-3-(cyclopropylmethoxy)benzamide;
1-[4-cyclopropyl-3-(cyclopropylmethoxy)benzoyl]-4,4-difluoro-L-prolinamide;
N-(3-carbamoylpentan-3-yl)-4-cyclopropyl-3-(cyclopropylmethoxy)benzamide;
N2-[4-cyclopropyl-3-(cyclopropylmethoxy)benzoyl]-N-methyl-L-leucinamide;
4-cyclopropyl-3-(cyclopropylmethoxy)-N-[(2S)-1-(methanesulfonyl)-2-(5-methyl-1,2,4-oxadiazol-3-yl)propan-2-yl]benzamide;
4-cyclopropyl-3-(cyclopropylmethoxy)-N-[(2R)-1-(methanesulfonyl)-2-(5-methyl-1,2,4-oxadiazol-3-yl)propan-2-yl]benzamide;
5-[4-cyclopropyl-3-(cyclopropylmethoxy)benzoyl]-5-azaspiro[2.4]heptane-6-carboxamide;
5-tert-butyl-3-[4-cyclopropyl-3-(2,2,2-trifluoroethoxy)phenyl]-1,2,4-oxadiazole;
5-tert-butyl-3-[4-cyclopropyl-3-(2,2-difluoroethoxy)phenyl]-1,2,4-oxadiazole;
4-cyclopropyl-N-[(2R)-1-cyclopropyl-2-(5-methyl-1,2,4-oxadiazol-3-yl)propan-2-yl]-3-(2,2,2-trifluoroethoxy)benzamide;
4-cyclopropyl-N-[(2S)-1-cyclopropyl-2-(5-methyl-1,2,4-oxadiazol-3-yl)propan-2-yl]-3-(2,2,2-trifluoroethoxy)benzamide;
N-[3-(2-amino-2-oxoethyl)-1,1-dioxo-thietan-3-yl]-4-cyclopropyl-3-(2,2,2-trifluoroethoxy)benzamide;
4-cyclopropyl-N-[(2R)-1-(methanesulfonyl)-2-(5-methyl-1,2,4-oxadiazol-3-yl)propan-2-yl]-3-(2,2,2-trifluoroethoxy)benzamide;
4-cyclopropyl-N-[(2S)-1-(methanesulfonyl)-2-(5-methyl-1,2,4-oxadiazol-3-yl)propan-2-yl]-3-(2,2,2-trifluoroethoxy)benzamide;
5-tert-butyl-3-[4-cyclopropyl-3-(2-fluoroethoxy)phenyl]-1,2,4-oxadiazole;
4-cyclopropyl-N-[(2R)-1-cyclopropyl-2-(5-methyl-1,2,4-oxadiazol-3-yl)propan-2-yl]-3-(2,2-difluoroethoxy)benzamide;
4-cyclopropyl-N-[(2S)-1-cyclopropyl-2-(5-methyl-1,2,4-oxadiazol-3-yl)propan-2-yl]-3-(2,2-difluoroethoxy)benzamide;
4-cyclopropyl-N-[(2R)-1-cyclopropyl-2-(5-methyl-1,2,4-oxadiazol-3-yl)propan-2-yl]-3-(2-fluoroethoxy)benzamide;
4-cyclopropyl-N-[(2S)-1-cyclopropyl-2-(5-methyl-1,2,4-oxadiazol-3-yl)propan-2-yl]-3-(2-fluoroethoxy)benzamide;
N-[(2S)-4-amino-2-cyclopropyl-4-oxobutan-2-yl]-4-cyclopropyl-3-(2,2,2-trifluoroethoxy)benzamide;
N-[(2R)-4-amino-2-cyclopropyl-4-oxobutan-2-yl]-4-cyclopropyl-3-(2,2,2-trifluoroethoxy)benzamide;
4-cyclopropyl-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-3-[(propan-2-yl)oxy]benzamide;
4-cyclopropyl-N-[(2S)-1-cyclopropyl-2-(5-methyl-1,2,4-oxadiazol-3-yl)propan-2-yl]-3-[(propan-2-yl)oxy]benzamide;
4-cyclopropyl-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-3-(2-fluoroethoxy)benzamide;
1-[4-cyclopropyl-3-(2-fluoroethoxy)benzoyl]-4,4-difluoro-L-prolinamide;
4-cyclopropyl-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-3-(2,2,2-trifluoroethoxy)benzamide;
1-[4-cyclopropyl-3-(2,2,2-trifluoroethoxy)benzoyl]-4,4-difluoro-L-prolinamide;
N-[(2S)-4-amino-2-cyclopropyl-4-oxobutan-2-yl]-4-cyclopropyl-3-[(propan-2-yl)oxy]benzamide;
N-[(2R)-4-amino-2-cyclopropyl-4-oxobutan-2-yl]-4-cyclopropyl-3-[(propan-2-yl)oxy]benzamide;
N-[(2R)-4-amino-2-cyclopropyl-4-oxobutan-2-yl]-4-cyclopropyl-3-(2-fluoroethoxy)benzamide;
3-tert-butyl-5-{4-cyclopropyl-3-[(propan-2-yl)oxy]phenyl}-1,2,4-oxadiazole;
3-tert-butyl-5-[4-cyclopropyl-3-(3,3-difluoropyrrolidin-1-yl)phenyl]-1,2,4-oxadiazole;
1-{4-cyclopropyl-3-[(propan-2-yl)oxy]benzoyl}-4,4-difluoro-L-prolinamide;
4-cyclopropyl-N-[(2R)-1-cyclopropyl-2-(5-methyl-1,2,4-oxadiazol-3-yl)propan-2-yl]-3-[(propan-2-yl)oxy]benzamide;
4-cyclopropyl-N-[(2R)-1-cyclopropyl-2-(5-methyl-1,2,4-oxadiazol-3-yl)propan-2-yl]-3-(6-fluoropyridin-3-yl)benzamide;
N-[(2S)-4-amino-2-cyclopropyl-4-oxobutan-2-yl]-4-cyclopropyl-3-(2,2,2-trifluoroethoxy)benzamide;
N-[(2R)-4-amino-2-cyclopropyl-4-oxobutan-2-yl]-4-cyclopropyl-3-(6-fluoropyridin-3-yl)benzamide;
N-[(2S)-4-amino-2-cyclopropyl-4-oxobutan-2-yl]-4-cyclopropyl-3-(6-fluoropyridin-3-yl)benzamide;
N-[(2S)-4-amino-2-cyclopropyl-4-oxobutan-2-yl]-4-cyclopropyl-3-(2-fluoroethoxy)benzamide;
1-[4-cyclopropyl-3-(1-methyl-1H-pyrazol-5-yl)benzoyl]-4,4-difluoro-L-prolinamide;
4-cyclopropyl-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-3-(1-methyl-1H-pyrazol-5-yl)benzamide;
1-[4-cyclopropyl-3-(6-fluoropyridin-3-yl)benzoyl]-4,4-difluoro-L-prolinamide;
4-cyclopropyl-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-3-(6-fluoropyridin-3-yl)benzamide;
4-cyclopropyl-N-[(2S)-1-cyclopropyl-2-(5-methyl-1,2,4-oxadiazol-3-yl)propan-2-yl]-3-(1-methyl-1H-pyrazol-5-yl)benzamide;
4-cyclopropyl-N-[(2S)-1-cyclopropyl-2-(5-methyl-1,2,4-oxadiazol-3-yl)propan-2-yl]-3-(6-fluoropyridin-3-yl)benzamide;
N-[(2R)-4-amino-2-cyclopropyl-4-oxobutan-2-yl]-4-cyclopropyl-3-(3,3-difluoropyrrolidin-1-yl)benzamide;
N-[(2S)-4-amino-2-cyclopropyl-4-oxobutan-2-yl]-4-cyclopropyl-3-(3,3-difluoropyrrolidin-1-yl)benzamide;
4-cyclopropyl-N-[(2R)-1-cyclopropyl-2-(5-methyl-1,2,4-oxadiazol-3-yl)propan-2-yl]-3-(3,3-difluoropyrrolidin-1-yl)benzamide;
4-cyclopropyl-N-[(2S)-1-cyclopropyl-2-(5-methyl-1,2,4-oxadiazol-3-yl)propan-2-yl]-3-(3,3-difluoropyrrolidin-1-yl)benzamide;
1-[4-cyclopropyl-3-(3,3-difluoropyrrolidin-1-yl)benzoyl]-4,4-difluoro-L-prolinamide;
4-cyclopropyl-3-(3,3-difluoropyrrolidin-1-yl)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]benzamide;
4-cyclopropyl-N-[(5-methyl-1,2,4-oxadiazol-3-yl)(3-methyloxetan-3-yl)methyl]-3-(2,2,2-trifluoroethoxy)benzamide;
4-cyclopropyl-N-[(5-methyl-1,2,4-oxadiazol-3-yl)(3-methyloxetan-3-yl)methyl]-3-[(propan-2-yl)oxy]benzamide;
N-[3-amino-1-(3-methyloxetan-3-yl)-3-oxopropyl]-4-cyclopropyl-3-(2,2,2-trifluoroethoxy)benzamide; and
4-cyclopropyl-3-(2-fluoroethoxy)-N-[(5-methyl-1,2,4-oxadiazol-3-yl)(3-methyloxetan-3-yl)methyl]benzamide,
or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 1)

The compound according to claim 1, wherein the compound is selected from the group consisting of:
N2-[4-cyclopropyl-3-(cyclopropylmethoxy)benzoyl]-L-leucinamide;
4-cyclopropyl-3-(cyclopropylmethoxy)-N-(1-hydroxy-2-methylpropan-2-yl)benzamide;
3-tert-butyl-5-[4-cyclopropyl-3-(cyclopropylmethoxy)phenyl]-1,2,4-oxadiazole;
N-[3-(2-amino-2-oxoethyl)oxetan-3-yl]-4-cyclopropyl-3-(cyclopropylmethoxy)benzamide;
N-[3-(2-amino-2-oxoethyl)-1,1-dioxothietan-3-yl]-4-cyclopropyl-3-(cyclopropylmethoxy)benzamide;
1-[4-cyclopropyl-3-(cyclopropylmethoxy)benzoyl]-4,4-difluoro-L-prolinamide;
5-tert-butyl-3-[4-cyclopropyl-3-(2-fluoroethoxy)phenyl]-1,2,4-oxadiazole;
N-[(2S)-4-amino-2-cyclopropyl-4-oxobutan-2-yl]-4-cyclopropyl-3-(2,2,2-trifluoroethoxy)benzamide;
4-cyclopropyl-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-3-[(propan-2-yl)oxy]benzamide;
4-cyclopropyl-N-[(2S)-1-cyclopropyl-2-(5-methyl-1,2,4-oxadiazol-3-yl)propan-2-yl]-3-[(propan-2-yl)oxy]benzamide; and
N-[(2R)-4-amino-2-cyclopropyl-4-oxobutan-2-yl]-4-cyclopropyl-3-[(propan-2-yl)oxy]benzamide,
or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 1)

A process for the preparation of a compound according to claim 1, comprising one of the following steps:
(a) reacting a compound of formula (A)
in the presence of H2N—C(R4R5)—R6, a coupling agent and a base, wherein R2 is cyclopropylmethoxy, alkoxy or haloalkoxy;
(b) reacting a compound of formula (A) as defined above in the presence of H—R7, a coupling agent and a base, wherein R2 is cyclopropylmethoxy, alkoxy or haloalkoxy;
(c) reacting a compound of formula (A) as defined above in the presence of a compound of formula (B)
and carbonydiimidazole, wherein R8′ is methyl or tert-butyl; or
(d) reacting a compound of formula (C)
in the presence of R2′—X, wherein R2′ is cyclopropylmethyl, alkyl or haloalkyl, R8′ is methyl or tert-butyl and X is a leaving group.

### Claim 14 (depends on 13)

A compound manufactured according to a process of claim 13.

### Claim 15

(canceled)

### Claim 16 (depends on 1)

A pharmaceutical composition comprising a compound in accordance with claim 1, or a pharmaceutically acceptable salt or ester thereof, and a therapeutically inert carrier.

### Claim at position 17

-19. (canceled)

### Claim 20 (depends on 1)

A method for the treatment or prophylaxis of pain, atherosclerosis, age-related macular degeneration, diabetic retinopathy, glaucoma, diabetes mellitus, inflammation, inflammatory bowel disease, ischemia-reperfusion injury, acute liver failure, liver fibrosis, lung fibrosis, kidney fibrosis, systemic fibrosis, acute allograft rejection, chronic allograft nephropathy, diabetic nephropathy, glomerulonephropathy, cardiomyopathy, heart failure, myocardial ischemia, myocardial infarction, systemic sclerosis, thermal injury, burning, hypertrophic scars, keloids, gingivitis pyrexia, liver cirrhosis or tumors, regulation of bone mass, neurodegeneration, stroke, transient ischemic attack or uveitis, which method comprises administering to a patient in need thereof an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt or ester thereof.

### Claim 21

(canceled)
